Rapamycin Delays Xenogeneic Acute Graft Versus Host Disease (aGVHD) in Nod/Scid/Il2RγNull (NSG) Mice: Impact of Regulatory T Cells  by Bruck, F. et al.
S332 Poster Session IIspleen and CD4+ Th17 cytokine (IL-17) elevation in the thymic
compartment of recipients that received S-59 treated T cells
(mean-28.44pg/ml versus 1.45pg/ml, p 5 0.0059). In-vivo track-
ing of S-59 treated T cells demonstrated the disappearance of
these cells in the peripheral blood, spleen, bone marrow and thy-
mus within 48 hours of transplantation. Nonetheless, we noted
that recipients of S-59 treated T cells had significantly less acute
GVHD and better overall survival (p 5 0.0001). In-vitro co-cul-
tures of stem cells (HSC) with S-59 T cells demonstrated signif-
icant increase in multilineage CFU formation(p \ 0.0001). In
summary, our experiments indicate that there is an initial domi-
nance of inflammatory and CD4 Th1 cytokines immediately
post transplantation. Co-transplantation of S-59 treated T cells
shifts the effector CD4 T cell profile to resemble a Treg pheno-
type. Thus, S-59 treated T cells appear to exert an important
immunomodulatory effect to ameliorate GVHD and improve
survival after MHC-mismatched allogeneic transplantation. In
addition these T cells exert a direct proliferative effect on the
HSCs.
Table 1. Cytokine Profile
Peripheral blood Bone marrow ThymocyteTGF-b [S59] 8482.7 pg/ml 7062.1pg/ml 2926.9pg/ml
TGF-b [control] 1.1pg/ml 301.55 pg/ml 46.5 pg/ml
IL-10 [S59] 419.0 pg/ml 174.0 30.4pg/ml
IL-10 [control] <1pg/ml 82.1pg/ml 33.44pg/mlp value- * 0.0001, **0.0006497
SIROLIMUS INDUCES COMPLETE REMISSION OF ACUTE GRAFT-VERSUS-
HOST DISEASE WITHOUT SYSTEMIC GLUCOCORTICOIDS
Pidala, J., Tomblyn, M., Nishihori, T., Perkins, J., Field, T., Ayala, E.,
Alsina, M., Ochoa, L., Locke, F., Perez, L., Fernandez, H., Anasetti, C.
Moffitt Cancer Center, Tampa, FL
While glucocorticoids have been considered essential in pri-
mary therapy of acute graft-versus-host disease (aGVHD), com-
plete remission from aGVHD is achieved in the minority of
cases. Sirolimus is a potent immunosuppressive agent which
may provide a novel approach to primary aGVHD therapy. In
a retrospective analysis, we examined the efficacy of sirolimus
as sole primary therapy for aGVHD. A total of 32 allogeneic
peripheral blood stem cell recipients (78% unrelated donors,
16% with 1-2 antigen mismatch) with biopsy confirmed aGVHD
were treated with sirolimus at a median of 30 days (range 15 –
106) after allogeneic hematopoietic cell transplantation (HCT).
Median age was 60 years (range 28–73). Patients were at high
risk for relapse of primary malignancy, with 23/32 not in remis-
sion at time of HCT. Sirolimus was delivered orally to achieve
serum levels of 4-12ng/mL. Therapeutic serum levels of siroli-
mus were achieved in all cases, including those with GI involve-
ment. All patients had tacrolimus based aGVHD prophylaxis;
target tacrolimus level was reduced to 3-7ng/mL once sirolimus
was initiated. Complete remission (CR) was defined as complete
resolution of all aGVHD manifestations sustained for at least 4
weeks without the addition of glucocorticoids or other systemic
immune suppressive agents. At time of primary sirolimus therapy,
53% had skin involvement, 66% GI, and 16% hepatic. Overall
grade was 1 (12%), 2 (75%), and 3 (13%). Sixteen (50%) achieved
sustained CR of aGVHD following sirolimus treatment. CR did
not significantly differ according to organ involvement or overall
aGVHD severity. With median follow up time of 16 months
(range 6-26 months), one year OS was 56% (95% CI 38-74%).
Accounting for competing risk, the cumulative incidence of
relapse at one year was 37% (23-60%), and NRM was 20%
(10-42%). The cumulative incidence of any grade chronic
GVHD per NIH consensus criteria was 55% (39-79%). Throm-
botic microangiopathy occurred in three cases, which responded
to dose reduction or elimination of calcineurin inhibitor.
Sirolimus demonstrates activity that rivals that of high dose
glucocorticoids in the primary therapy of aGVHD.498
RAPAMYCIN DELAYS XENOGENEIC ACUTE GRAFT VERSUS HOST DISEASE
(AGVHD) IN NOD/SCID/IL2RgNULL (NSG) MICE: IMPACT OF REGULA-
TORY T CELLS
Bruck, F., Baron, F., Dubois, S., Briquet, A., Hanon-Absil, M., Belle, L.,
Menten, C., Beguin, Y., Humblet-Baron, S. University of Liege, Liege,
Liege, Belgium
Background: Rapamycin (RAPA), a mTOR inhibitor also termed
sirolimus, is a potent immunosuppressive drug which might induce
tolerance by inhibiting activated T cells but not regulatory (Treg)
T cells. The aims of the current study were to establish a humanized
model of aGVHD in NSG mice, and to assess the impact of RAPA
and Treg infusion/depletion on morbidity from xenogeneic
aGVHD.
Methods andResults:Wefirst assessed the impact of the dose of IV
infused human PBMC on GVHD mortality. After 2.5 Gy TBI irra-
diation NSG mice received 5105 (n 5 5), 1106 (n 5 5), 2106
(n 5 5) or 3106 (n 5 5) human PBMC. Mean survivals in each
group were 3667 days, 3066 days, 2465 days and 1661 days,
respectively. At time of death, mice presented clinical symptoms of
aGVHDsuch as weight loss higher than. 20%, and showedmassive
CD3+ humanT cells infiltration of their marrows, livers, spleens and
lungs. Based on these results, we decided to use 2106 PBMC for
further experiments. We then investigated whether injection of
RAPA or PBMC supplemented in Treg could mitigate aGVHD in
this model. After receiving 2.5 Gy TBI NSGmice were transplanted
with 2106 PBMC and i.p. PBS (control arm), with 2106 PBMC
and i.p. RAPA (rapa arm), with 2106 PBMC depleted in Treg
and i.p. RAPA (Treg-depleted arm), or with 2106 PBMC supple-
mented in Treg (1Treg:8PBMC) and i.p. PBS (Treg arm). Mice
were daily monitored for survival and weighed at least once a week
until sacrifice. Median survival was higher in the RAPA arm than
in the control arm (96 vs. 24 days, P \ 0.01), while mice given
Treg-depleted PBMC plus RAPA had a median survival of 48 days
(P\ 0.01 in comparison with the rapa arm). In contrast, mice in
the Treg arm had a median survival of 71 days (P\0.01 in compar-
ison with the control arm).
Conclusions: In summary, our data indicate that i.v. injection of
2106 PBMC into irradiatedNSGmice induced a severe xenogeneic
aGVHD. RAPA administration increased survival but this effect was
greatly affected byTreg depletion suggesting that RAPA administra-
tion prevented death fromGVHDat least in part by promotingTreg.499
STAT1 DEFICIENCY FAILS TO PROTECT AGAINST MURINE CHRONIC
GVHD
Foley, J.E., Amarnath, S., Felizardo, T.C., He, A., Fowler, D.H.
National Cancer Institute, Bethesda, MD
Donor Th1 cells, which play a key role in promoting acute
GVHD, may also contribute to chronic GVHD. To further charac-
terize the role of Th1 cells in cGVHD, we used a model developed
by the Drobyski Lab whereby acute GVHD is initiated (B6 0
BALB/c BMT; 21-day transplant interval), with subsequent adoptive
transfer of post-BMT B6 T cells into syngeneic, immune-deficient
hosts (B6129s7-Rag1; 45-day observation interval) for induction of
auto-reactive, cGVHD. Because STAT1 is the signaling pathway
for the Th1-polarizing cytokines IFN-a and IL-12, we used
STAT1-deficient (KO) donor T cells to assess whether Th1 cell
deficiency might yield reduced cGVHD; other transplant cohorts
received T cells that were either wild-type (WT), STAT3-KO
(loss of Th17 function), or STAT6-KO (loss of Th2 function). Clin-
ical signs of acute GVHD (weight loss, hunched posture) was severe
in WT, mild in STAT3-KO, and STAT6-KO T cells; in contrast,
STAT1-KO T cell recipients showed no signs of acute GVHD.
Chronic GVHD, which was manifested by weight loss and extensive
skin disease (erythematous, scaling rash with alopecia; . 50% body
surface area), occurred in 100% of recipients of WT and STAT1-
KOT cells (5/5 and 10/10 cases, respectively); by comparison, exten-
sive skin disease was not observed in recipients of STAT3-KO or
STAT6-KO T cells (0/9 and 0/5 cases, respectively). As such,
STAT1-deficiency appeared to reduce acute GVHDbut not chronic
GVHD. Further experiments were performed at the end of the
cGVHD observation interval to confirm that recipients of
